American Thoracic Society, 2022
Safety and Efficacy of Efzofitimod (ATYR1923), a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial
American Thoracic Society, 2022
ATYR2810, a Fully Humanized Monoclonal Antibody Targeting the VEGF-NRP2 Pathway Sensitizes Highly Aggressive and Chemoresistant TNBC Subtypes to Chemotherapy
American Association for Cancer Research, 2022
ATYR2810 an Anti-NRP2 Monoclonal Antibody Targets Tumor Associated Macrophages
Society for Immunotherapy of Cancer, 2021
Immunomodulatory Protein ATYR1923 Disrupts an In-Vitro Model of Sarcoid Granuloma Formation
European Respiratory Society, 2021
Treatment with ATYR1923 Reduces Biomarkers in COVID-19 Pneumonia
European Respiratory Society, 2021
Engineering an Anti-Neuropilin-2 (NRP2) Antibody that Selectively Blocks NRP2 Interactions with Semaphorin and Plexin
Antibody Engineering & Therapeutics Europe, 2021
ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy
Keystone Symposia: Cancer Stem Cells, 2021
The Neuropilin-2 Targeting Antibody ATYR2810 Inhibits Non-Small Cell Lung Cancer Tumor Growth in Monotherapy and Combination Therapy
American Association for Cancer Research, 2021
A Domain-Specific Antibody to NRP2 Down-Regulated Epithelial-Mesenchymal Transition Genes and Enhanced Efficacy of Standard-of-Care Therapeutics for Aggressive Breast Cancer
American Association for Cancer Research, 2021